Aprea Therapeutics, INC 8-K filings

Aprea Therapeutics reported Q2 2026 results, noting accelerated enrollment in its Phase 1 APR-1051 trial and early signs of clinical activity.

Aprea Therapeutics has received an additional 180-day period from Nasdaq to regain compliance with the minimum bid price requirement.

Aprea Therapeutics held its 2026 annual meeting, with stockholders approving key proposals including a reverse stock split authorization and director elections.

Aprea Therapeutics announced first quarter 2026 financial results, highlighting two partial responses in its APR-1051 trial and a $30 million oversubscribed private placement to fund ongoing development.

Aprea Therapeutics announced the closing of an oversubscribed $30 million private placement to fund the development of its lead oncology program, APR-1051.

Aprea Therapeutics announced fourth quarter and full year 2025 financial results, highlighted by early clinical proof-of-concept for its WEE1 inhibitor APR-1051 and a strengthened cash position.

Aprea Therapeutics announced a $5.6 million private placement and early clinical proof-of-concept for its WEE1 inhibitor, APR-1051, including an unconfirmed partial response in an endometrial cancer patient.

Aprea Therapeutics, Inc. received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Aprea Therapeutics provides a corporate presentation detailing progress in its precision oncology pipeline, focusing on DDR inhibition with APR-1051 and ATRN-119.

Aprea Therapeutics, a clinical-stage biopharmaceutical company, announced a $3.1 million private placement of common stock and warrants with new and existing healthcare-focused investors and company insiders.

Aprea Therapeutics announced its third quarter 2025 financial results and provided updates on its WEE1 and ATR inhibitor clinical programs, extending its cash runway into Q4 2026.

Aprea Therapeutics announced early signals of activity for its WEE1 Kinase Inhibitor APR-1051 in the ACESOT-1051 trial, with 3 out of 4 patients achieving stable disease at the 100 mg dose level.

Aprea Therapeutics announced the recommended Phase 2 dose for ATRN-119 and will now focus on combination therapies, while advancing its WEE1 inhibitor, APR-1051.

Aprea Therapeutics, Inc. provided an update on its clinical pipeline, financial position, and strategic milestones, highlighting early positive signals for its WEE1 and ATR inhibitors.

Aprea Therapeutics reported second quarter 2025 financial results and provided clinical updates for its lead oncology programs, APR-1051 and ATRN-119, showing early signs of disease control and tumor shrinkage.

Aprea Therapeutics, Inc. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, where all proposed resolutions, including the election of three Class III directors and the ratification of its independent accounting firm, were approved.

Aprea Therapeutics announces encouraging early clinical data for its ATR inhibitor, ATRN-119, and WEE1 inhibitor, APR-1051, while extending its cash runway into early Q2 2026.

Aprea Therapeutics announced its Q4 and full year 2024 financial results, highlighting progress in clinical trials for APR-1051 and ATRN-119, and a cash balance of $22.8 million.

Aprea Therapeutics provides an update on its patent portfolio, highlighting its commitment to innovation in DNA Damage Response (DDR) therapeutics.

Aprea Therapeutics announced a cash balance of $22.8 million as of December 31, 2024, and provided updates on its clinical programs for WEE1 and ATR inhibitors.

Aprea Therapeutics has entered into an agreement to sell up to $3 million of its common stock through an at-the-market offering.

Aprea Therapeutics announced positive preliminary results from its Phase 1 trial of APR-1051, a WEE1 inhibitor, and provided updates on its ATR inhibitor, ATRN-119, along with its third quarter 2024 financial results.

Aprea Therapeutics reports that its WEE1 inhibitor, APR-1051, shows promising preliminary safety results in an ongoing Phase 1 clinical trial, with no hematologic toxicity observed.

Aprea Therapeutics announced the appointment of a new Senior Medical Advisor, a change in Chief Medical Officer, and provided a preliminary cash balance update.

Aprea Therapeutics reported its second quarter 2024 financial results, highlighted by the initiation of a Phase 1 trial for APR-1051 and a cash runway extended into Q4 2025.

Aprea Therapeutics held its 2024 annual meeting, electing three Class II directors and ratifying its independent auditor.

Aprea Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial evaluating the oral WEE1 inhibitor APR-1051 for advanced solid tumors.

Aprea Therapeutics reported its first quarter 2024 financial results, highlighted by FDA clearance for APR-1051 and progress in the ATRN-119 clinical trial.

Aprea Therapeutics announced details of four poster presentations at the AACR Annual Meeting, showcasing their next-generation WEE1 inhibitor, APR-1051, and a novel macrocyclic ATR inhibitor, ATRN-119.

Aprea Therapeutics announced positive financial results for 2023, progress in clinical trials for its ATR and WEE1 inhibitors, and a $16 million private placement.